Pyrazolanthrone (SP600125)
SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. SP600125 inhibits autophagy and activates apoptosis.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Front Pharmacol.2021, 12:635510.
Journal of Pharmaceutical Investigation2024, 024-00662-1.
Food Research International2023, 113792.
Appl Microbiol Biotechnol.2018, 102(12):5105-5120
Evid Based Complement Alternat Med.2016, 2016:1230294
J Adv Res.2019, 17:85-94
Molecules.2017, 22(3)
J Food Drug Anal.2023, 31(2):254-277.
Sci Rep.2021, 11(1):11936.
Front Pharmacol.2023, 14:1095083.
Related and Featured Products
Proc Natl Acad Sci U S A,2001 Nov 20;98(24):13681-6.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.[Pubmed:
11717429]
Jun N-terminal kinase (JNK) is a stress-activated protein kinase that can be induced by inflammatory cytokines, bacterial endotoxin, osmotic shock, UV radiation, and hypoxia.
METHODS AND RESULTS:
We report the identification of an anthrapyrazolone series with significant inhibition of JNK1, -2, and -3 (K(i) = 0.19 microM). SP600125 is a reversible ATP-competitive inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures. In animal studies, SP600125 blocked (bacterial) lipopolysaccharide-induced expression of tumor necrosis factor-alpha and inhibited anti-CD3-induced apoptosis of CD4(+) CD8(+) thymocytes.
CONCLUSIONS:
Our study supports targeting JNK as an important strategy in inflammatory disease, apoptotic cell death, and cancer.
Cancer Res, 2010, 70(24),10255-64.
Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.[Pubmed:
21159646]
Cell lines: HCT116, A2780, and U2OS cells
Concentrations: 0–5 μM, dissolved in 0.1% DMSO
Incubation Time: 72 hours
Method:
Cells are seeded in 384 well-plates. One day after seeding, the cells are treated with SP600125 for 72 hours and the plates are then processed using a CellTiter-Glo assay. Inhibitory activity is evaluated comparing treated versus control data and IC50 value of proliferation is calculated.
Proc Natl Acad Sci U S A, 2001 Nov 20;98(24):13681-6.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.[Pubmed:
11717429]
Animal Models: Mouse LPS/TNF model (female CD-1)
Dosages:15 or 30 mg/kg
Administration: Administered via intravenous injection or orally
